Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
J. John Mann & Mina M. Rizk. (2023) Rethinking the medication management of major depression. Expert Review of Neurotherapeutics 23:4, pages 331-363.
Read now
Read now
Alexandrine Corriger & Gisèle Pickering. (2019) Ketamine and depression: a narrative review. Drug Design, Development and Therapy 13, pages 3051-3067.
Read now
Read now
Kai Zhang & Kenji Hashimoto. (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Review of Neurotherapeutics 19:1, pages 83-92.
Read now
Read now
Articles from other publishers (58)
Alexandre Paim Diaz, Joao Quevedo, Marsal Sanches & Jair C. Soares. 2024. Clinical Textbook of Mood Disorders. Clinical Textbook of Mood Disorders
193
205
.
Salam Hussain, Suneel Chamoli, Paul Fitzgerald, Ashu Gandhi, Shane Gill, Shanthi Sarma & Colleen Loo. (2024) Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of repetitive transcranial magnetic stimulation. Australian & New Zealand Journal of Psychiatry.
Crossref
Crossref
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco, Andrea Aguglia, Gaetano Catania, Carmen Concerto, Alessandro Cuomo, Andrea Fagiolini, Giuseppe Lanza, Ludovico Mineo, Antimo Natale, Laura Rapisarda, Antonino Petralia, Maria Salvina Signorelli & Eugenio Aguglia. (2024) Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. Frontiers in Psychiatry 15.
Crossref
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D. Henter & Carlos A. ZarateJrJr. (2023) Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology 49:1, pages 23-40.
Crossref
Crossref
Chaohui Zhen, Chong Wang, Yanjun Ma, Yuli Pang, Feiyue Cai, Jiali Meng, Yuefei He, Ping Xiao, Jianxi Liu, Xi Mei, Shupeng Li, Guanzheng Wu, Guangzhen Jin, Biao Zheng, Rui Liang & Zhen Tan. (2023) Mechanism of Antidepressant Action of (2R,6R)-6-Hydroxynorketamine (HNK) and Its Compounds: Insights from Proteomic Analysis. Molecular Neurobiology 61:1, pages 465-475.
Crossref
Crossref
Paul B Fitzgerald & Saxby Pridmore. (2022) Letter to the Editor regarding ‘Five facts about rTMS?’. Australian & New Zealand Journal of Psychiatry 57:2, pages 303-304.
Crossref
Crossref
Amit Chail, PookalaS Bhat, Harpreet Singh & RajivKumar Saini. (2023) Comparative efficacy of high-frequency repetitive transcranial magnetic stimulation to left dorsolateral prefrontal cortex as an augmentation strategy versus pharmacological augmentation in non-psychotic, unipolar, treatment-resistant depression: A randomized controlled trial. Industrial Psychiatry Journal 32:1, pages 93.
Crossref
Crossref
Regina Taurines, Christoph Wewetzer & Gerd Schulte-Körne. 2023. Neuro-/Psychopharmaka im Kindes- und Jugendalter. Neuro-/Psychopharmaka im Kindes- und Jugendalter
563
577
.
Stevan Nikolin, Kieran Owens, Rohan Francis-Taylor, Anna Chaimani, Donel M Martin, Michael Bull, Harold A Sackeim, Declan M McLoughlin, Pascal Sienaert, Charles H Kellner & Colleen Loo. (2022) Comparative efficacy, cognitive effects and acceptability of electroconvulsive therapies for the treatment of depression: protocol for a systematic review and network meta-analysis. BMJ Open 12:12, pages e068313.
Crossref
Crossref
Paul B Fitzgerald, Shane Gill, Michael Breakspear, Jayashri Kulkarni, Leo Chen, Saxby Pridmore, Subramanian Purushothaman, Cherrie Galletly, Patrick Clarke, Felicity Ng, Salam Hussain, Suneel Chamoli, Tibi Csizmadia, Patrick Tolan, Luca Cocchi, Samir Ibrahim OAM, Kavitha Shankar, Shanthi Sarma, Michael Lau, Colleen Loo, Tarun Yadav & Kate E Hoy. (2021) Revisiting the effectiveness of repetitive transcranial magnetic stimulation treatment in depression, again. Australian & New Zealand Journal of Psychiatry 56:8, pages 905-909.
Crossref
Crossref
Paul B Fitzgerald, Mark S George & Saxby Pridmore. (2021) The evidence is in: Repetitive transcranial magnetic stimulation is an effective, safe and well-tolerated treatment for patients with major depressive disorder. Australian & New Zealand Journal of Psychiatry 56:7, pages 745-751.
Crossref
Crossref
Jan Jacobus Muit, Philip F P van Eijndhoven, Andrea Cipriani, Iris Dalhuisen, Suzanne van Bronswijk, Toshi A Furukawa & Henricus G Ruhe. (2022) Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis. BMJ Open 12:4, pages e056777.
Crossref
Crossref
Antonio Del Casale, Leda Marina Pomes, Luca Bonanni, Federica Fiaschè, Clarissa Zocchi, Alessio Padovano, Ottavia De Luca, Gloria Angeletti, Roberto Brugnoli, Paolo Girardi, Robert Preissner, Marina Borro, Giovanna Gentile, Maurizio Pompili & Maurizio Simmaco. (2022) Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study. Journal of Personalized Medicine 12:2, pages 316.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Zümrüt Duygu Sen, Lena Vera Danyeli & Martin Walter. 2022. Therapieresistenz bei Depressionen und bipolaren Störungen. Therapieresistenz bei Depressionen und bipolaren Störungen
181
201
.
Paul B. Fitzgerald & Z. Jeff DaskalakisPaul B. Fitzgerald & Z. Jeff Daskalakis. 2022. rTMS Treatment for Depression. rTMS Treatment for Depression
29
47
.
Klaus Munkholm, Karsten Juhl Jørgensen & Asger Sand Paludan-Müller. (2021) Adverse effects of electroconvulsive therapy. Cochrane Database of Systematic Reviews 2021:12.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
305
450
.
Paul B. Fitzgerald. (2021) Advancing the use of non-invasive brain stimulation through systematic data review. Brazilian Journal of Psychiatry 43:5, pages 458-459.
Crossref
Crossref
Fan-Zhen Kong, Cai-Fang Ji, Xiang-Dong Du, Robert Logan, Hui-Ying Zhao, Guan-Hui Wu, Yan-Song Liu, Zhen Tang & Mei-E Niu. (2021) Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance. Aging 13:17, pages 21400-21407.
Crossref
Crossref
Marlies E Alvarenga, Barbara M Murphy & Alun C Jackson. (2021) Emerging approaches to the treatment of depression in patients with cardiovascular disease. British Journal of Cardiac Nursing 16:9, pages 1-4.
Crossref
Crossref
Afifa Humaira, Sihaoyu Gao, Elizabeth Gregory, Lisa Ridgway, Daniel M. Blumberger, Jonathan Downar, Zafiris J. Daskalakis, Nicholas J. Ainsworth, Lang Wu, Michael Butterfield & Fidel Vila-Rodriguez. (2021) A patient-oriented analysis of pain side effect: A step to improve the patient's experience during rTMS?. Brain Stimulation 14:5, pages 1147-1153.
Crossref
Crossref
Ashley A. Conley, Amber E. Q. Norwood, Thomas C. Hatvany, James D. Griffith & Kathryn E. Barber. (2021) Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology 238:7, pages 1737-1752.
Crossref
Crossref
C. Danielle Jones, Robert Motl & Brian M. Sandroff. (2021) Depression in multiple sclerosis: Is one approach for its management enough?. Multiple Sclerosis and Related Disorders 51, pages 102904.
Crossref
Crossref
Tomoyuki Nakamura, Masaru Tomita, Naoki Horikawa, Masatoshi Ishibashi, Ken Uematsu, Teruyuki Hiraki, Toshi Abe & Naohisa Uchimura. (2021) Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression. Neuropsychopharmacology Reports 41:2, pages 168-178.
Crossref
Crossref
Idriss Ali Abdoulaye, Shan-shan Wu, Enkhmurun Chibaatar, Da-fan Yu, Kai Le, Xue-jin Cao & Yi-jing Guo. (2021) Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model. Neural Plasticity 2021, pages 1-17.
Crossref
Crossref
Gin S Malhi, Erica Bell, Zola Mannie, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Roger Mulder, Richard J Porter, Ajeet B Singh & Bill Lyndon. (2021) Profiling rTMS: A critical response. Australian & New Zealand Journal of Psychiatry 55:4, pages 355-365.
Crossref
Crossref
Paul B Fitzgerald, Shane Gill, Salam Hussain, Shanthi Sarma, Suneel Chamoli, Alan Weiss, David Garside, Subramanian Purushothaman, Matthew Fasnacht, Brett Simpson, Tibi Csizmadia, Carol Dean & Colleen Loo. (2021) The place of non-invasive brain stimulation in the RANZCP clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 55:4, pages 349-354.
Crossref
Crossref
Zsolt Turi, Claus Normann, Katharina Domschke & Andreas Vlachos. (2021) Transcranial Magnetic Stimulation in Psychiatry: Is There a Need for Electric Field Standardization?. Frontiers in Human Neuroscience 15.
Crossref
Crossref
Anees Bahji, Gustavo H. Vazquez & Carlos A. ZarateJrJr. (2021) Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?. Journal of Affective Disorders 282, pages 258-260.
Crossref
Crossref
Jessica L. West, Geoffrey Tremont, Ivan W. Miller & Lisa A. Uebelacker. (2020) Yoga v Health Education for Attentional Processes Relevant to Major Depressive Disorder. Mindfulness 12:3, pages 604-612.
Crossref
Crossref
Ana C Lucchese, Luciana M Sarin, Eduardo J Muniz Magalhães, Lorena C Del Sant, Camila B Puertas, Marco A Tuena, Carolina Nakahira, Victor AR Fava, Rodrigo Delfino, Juliana Surjan, Matheus S Steiglich, Matheus Barbosa, Guilherme Abdo, Frederico M Cohrs, Aroldo Liberatori, José A Del Porto, Acioly LT Lacerda & Sergio B Andreoli. (2021) Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. Journal of Psychopharmacology 35:2, pages 142-149.
Crossref
Crossref
Klaus Munkholm, Karsten Juhl Jørgensen & Asger Sand Paludan-Müller. (2021) Electroconvulsive therapy for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Valeria Bortolotto, PierLuigi Canonico & Mariagrazia Grilli. (2021)
β
2
and α
2
adrenergic receptors mediate the proneurogenic in vitro effects of norquetiapine
. Neural Regeneration Research 16:10, pages 2041.
Crossref
Crossref
M.A. Tumova, L.M. Muslimova, V.V. Stanovaya, A.K. Abdyrakhmanova & M.V. Ivanov. (2021) Contemporary methods of non-drug therapy for depression. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:5, pages 91.
Crossref
Crossref
Andreas Heinecke, Marta Tallarita & Maria De Iorio. (2020) Bayesian splines versus fractional polynomials in network meta-analysis. BMC Medical Research Methodology 20:1.
Crossref
Crossref
Paul B. Fitzgerald. (2020) An update on the clinical use of repetitive transcranial magnetic stimulation in the treatment of depression. Journal of Affective Disorders 276, pages 90-103.
Crossref
Crossref
Qingqing Cheng, Jihan Huang, Ling Xu, Yunfei Li, Huafang Li, Yifeng Shen, Qingshan Zheng & Lujin Li. (2020) Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. International Journal of Neuropsychopharmacology 23:2, pages 76-87.
Crossref
Crossref
Hatice Guncu Kurt, Murat Altinay & Amit Anand. (2020) Comparative Efficacy of Ketamine in Treatment-Resistant Depression. Psychiatric Annals 50:2, pages 62-67.
Crossref
Crossref
Brett Y. Lu, James R. Agapoff, Daniel J. Olson, Steven R. Williams, Adam Roller & Deborah Goebert. (2020) Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. Journal of Affective Disorders 262, pages 40-42.
Crossref
Crossref
Foluso AgboolaSteven J. Atlas, Daniel R. TouchetteKatherine FazioliSteven D. Pearson. (2020) The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy 26:1, pages 16-20.
Crossref
Crossref
Mohammed S Salahudeen, Cameron M Wright & Gregory M Peterson. (2020) Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Therapeutic Advances in Drug Safety 11, pages 204209862093789.
Crossref
Crossref
Lijia Chang, Yan Wei & Kenji Hashimoto. 2020. Ketamine. Ketamine
105
125
.
Thu Ha Pham & Alain M. Gardier. (2019) Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacology & Therapeutics 199, pages 58-90.
Crossref
Crossref
Kah Kheng Goh, Chun-Hsin Chen, Yi-Hang Chiu & Mong-Liang Lu. (2019) Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. Journal of Psychopharmacology 33:6, pages 700-713.
Crossref
Crossref
Mariusz Papp, Piotr Gruca, Magdalena Lason, Monika Niemczyk & Paul Willner. (2019) The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression. Journal of Psychopharmacology 33:6, pages 748-756.
Crossref
Crossref
Muhammad Ishrat Husain, Rebecca Strawbridge, Ben Carter, Brett D M Jones, Allan Young & Andre F Carvalho. (2019) Efficacy and acceptability of adjunctive psychological and pharmacological interventions for treatment-resistant depression: protocol for a systematic review and network meta-analysis. BMJ Open 9:5, pages e028538.
Crossref
Crossref
Rebecca Strawbridge, Ben Carter, Lindsey Marwood, Borwin Bandelow, Dimosthenis Tsapekos, Viktoriya L. Nikolova, Rachael Taylor, Tim Mantingh, Valeria de Angel, Fiona Patrick, Anthony J. Cleare & Allan H. Young. (2018) Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. British Journal of Psychiatry 214:1, pages 42-51.
Crossref
Crossref
Michael Cronquist Christensen, Ioana Florea, Annika Lindsten & David S Baldwin. (2018) Efficacy of vortioxetine on the physical symptoms of major depressive disorder. Journal of Psychopharmacology 32:10, pages 1086-1097.
Crossref
Crossref
Barbara J. Limandri. (2018) Treatment-Resistant Depression: Identification and Treatment Strategies. Journal of Psychosocial Nursing and Mental Health Services 56:9, pages 11-15.
Crossref
Crossref
F. Caraci, F. Calabrese, R. Molteni, L. Bartova, M. Dold, G. M. Leggio, C. Fabbri, J. Mendlewicz, G. Racagni, S. Kasper, M. A. Riva & F. Drago. (2018) International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacological Reviews 70:3, pages 475-504.
Crossref
Crossref
M P Dandekar, A J Fenoy, A F Carvalho, J C Soares & J Quevedo. (2018) Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Molecular Psychiatry 23:5, pages 1094-1112.
Crossref
Crossref
Zuleide Maria Ignácio, Ana Valquíria Calixto, Ritele Hernandez da Silva, João Quevedo & Gislaine Zilli Réus. (2018) The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies. Neuroscience & Biobehavioral Reviews 86, pages 36-50.
Crossref
Crossref
Taryn Williams, Dan J Stein & Jonathan Ipser. (2018) A systematic review of network meta-analyses for pharmacological treatment of common mental disorders. Evidence Based Mental Health 21:1, pages 7-11.
Crossref
Crossref
Kamaldeep Bhui. (2018) From the Editor's desk. The British Journal of Psychiatry 212:1, pages 64-64.
Crossref
Crossref
Ronald C. Kessler. (2018) The potential of predictive analytics to provide clinical decision support in depression treatment planning. Current Opinion in Psychiatry 31:1, pages 32-39.
Crossref
Crossref
Colleen Loo. (2018) Can we confidently use ketamine as a clinical treatment for depression?. The Lancet Psychiatry 5:1, pages 11-12.
Crossref
Crossref
Tonia L. Nicholls, Amanda Butler, Lindsey Kendrick-Koch, Johann Brink, Roland Jones & Alexander I. F. Simpson. 2018. The Practice of Correctional Psychology. The Practice of Correctional Psychology
9
37
.